Merck & Company

MRK-N

NYSE:MRK

76.37
0.18 (0.24%)
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme outside the United States and Canada, is an American pharmaceutical company and one of the largest pharmaceutical companies in the world.
More at Wikipedia

Analysis and Opinions about MRK-N

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
February 6, 2019
Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
Show full opinionHide full opinion
Merck & Company (MRK-N)
February 6, 2019
Merck vs. Pfizer Two large pharma companies that are treading water. A lot of the drugs they develop are coming off patent. You must look at their pipelines, with Merck doing very well while Pfizer has some good franchises, like Lipitor. Merck likely has the better pipeline. Neither has enough revenue growth or cash flow to entice him to buy.
PAST TOP PICK
PAST TOP PICK
December 3, 2018
(A Top Pick Jul 05/18, Up 29%) An investor should diversify in the health sector, and MRK is a diversified health company. MRK has done very well in their oncology side. They're becoming dominant in immunotherapies. MRK gets their science and data right, unlike their peers.
Show full opinionHide full opinion
Merck & Company (MRK-N)
December 3, 2018
(A Top Pick Jul 05/18, Up 29%) An investor should diversify in the health sector, and MRK is a diversified health company. MRK has done very well in their oncology side. They're becoming dominant in immunotherapies. MRK gets their science and data right, unlike their peers.
TOP PICK
TOP PICK
December 3, 2018
A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)
Show full opinionHide full opinion
Merck & Company (MRK-N)
December 3, 2018
A long-time top pick. Their entire business line works, particularly immunotherapies. It's had a great run. He writes covered calls on this to generate extra income. (Analysts’ price target is $81.25)
HOLD
HOLD
September 12, 2018

The small and mid-cap pharma sector has been on fire he says. On a relative basis, he believes, this may lead to acquisitions by the larger players. MRK-N has a big war chest to do this. He has not entered this space yet, but it is starting to check all his boxes for entry. He would suggest an ETF to diversify risk, especially at this stage of the cycle.

Show full opinionHide full opinion
Merck & Company (MRK-N)
September 12, 2018

The small and mid-cap pharma sector has been on fire he says. On a relative basis, he believes, this may lead to acquisitions by the larger players. MRK-N has a big war chest to do this. He has not entered this space yet, but it is starting to check all his boxes for entry. He would suggest an ETF to diversify risk, especially at this stage of the cycle.

TOP PICK
TOP PICK
July 13, 2018

He started buying in December and thinks the market has beaten the stock up over the Trump Administration move to curb pharmaceutical pricing. He thinks the market is underestimating sales growth. The sector is in a secular bull market. Yield 3.1%. (Analysts’ price target is $69.16)

Show full opinionHide full opinion

He started buying in December and thinks the market has beaten the stock up over the Trump Administration move to curb pharmaceutical pricing. He thinks the market is underestimating sales growth. The sector is in a secular bull market. Yield 3.1%. (Analysts’ price target is $69.16)

PAST TOP PICK
PAST TOP PICK
July 5, 2018

(A Top Pick September 14/17 - Down 4%) Nothing has changed. Still good dividends and fundamentals. Solid holding.

Show full opinionHide full opinion

(A Top Pick September 14/17 - Down 4%) Nothing has changed. Still good dividends and fundamentals. Solid holding.

TOP PICK
TOP PICK
July 5, 2018

Like the stability. They are one of the leaders in immunotherapy and other lines of business. Core holding. Dividend yield is 3.1%. Market cap $165.8 billion. (Analysts’ price target is $69.16)

Show full opinionHide full opinion

Like the stability. They are one of the leaders in immunotherapy and other lines of business. Core holding. Dividend yield is 3.1%. Market cap $165.8 billion. (Analysts’ price target is $69.16)

BUY
BUY
June 26, 2018

What healthcare stock to buy? In Canada, he likes Chartwell, in the U.S, Merck (MRK-N), and in Europe, Novo Nordisk.

Show full opinionHide full opinion

What healthcare stock to buy? In Canada, he likes Chartwell, in the U.S, Merck (MRK-N), and in Europe, Novo Nordisk.

TOP PICK
TOP PICK
April 30, 2018

He thinks the worst of the drugs going off patent is over. These guys have been really hurt by their patent cliff. It is a really good value name. He sees resistance at $67. It is a good sector to be in. (Analysts’ target: $68.79).

Show full opinionHide full opinion
Merck & Company (MRK-N)
April 30, 2018

He thinks the worst of the drugs going off patent is over. These guys have been really hurt by their patent cliff. It is a really good value name. He sees resistance at $67. It is a good sector to be in. (Analysts’ target: $68.79).

DON'T BUY
DON'T BUY
April 5, 2018

It is a stable stock with stable earnings. But the price momentum is weak.

Show full opinionHide full opinion

It is a stable stock with stable earnings. But the price momentum is weak.

TOP PICK
TOP PICK
March 21, 2018

A large, diversified pharma company with a hepatitis C franchise, but are really into immonotherapy and chemotherapy. They are getting positive results with their drugs, and will be the leader in this space. Own this with BMY-N and AZN-N preferrably (and not alone). A must-own stock in healthcare given their pipeline and leadership. Dividend yield of 3.5%. (Analysts' target of $67.25)

Show full opinionHide full opinion
Merck & Company (MRK-N)
March 21, 2018

A large, diversified pharma company with a hepatitis C franchise, but are really into immonotherapy and chemotherapy. They are getting positive results with their drugs, and will be the leader in this space. Own this with BMY-N and AZN-N preferrably (and not alone). A must-own stock in healthcare given their pipeline and leadership. Dividend yield of 3.5%. (Analysts' target of $67.25)

COMMENT
COMMENT
November 7, 2017

Unfortunately, pharmas/biotech have had a bit of a rough go. It was the mega-caps, not the small guys. This one reason he likes using ETF's in his mix. He prefers using the Spider S&P Biotech ETF (XBI-N).

Show full opinionHide full opinion
Merck & Company (MRK-N)
November 7, 2017

Unfortunately, pharmas/biotech have had a bit of a rough go. It was the mega-caps, not the small guys. This one reason he likes using ETF's in his mix. He prefers using the Spider S&P Biotech ETF (XBI-N).

TOP PICK
TOP PICK
September 14, 2017

He likes their leadership in drug therapies. They have their HEP-C and diabetes franchises. It is an easy hold for him. They are well diversified. They are number 3 in animal health products. It has a PE of 15.5 times next year’s earnings. (Analysts’ target: $70.00).

Show full opinionHide full opinion
Merck & Company (MRK-N)
September 14, 2017

He likes their leadership in drug therapies. They have their HEP-C and diabetes franchises. It is an easy hold for him. They are well diversified. They are number 3 in animal health products. It has a PE of 15.5 times next year’s earnings. (Analysts’ target: $70.00).

PAST TOP PICK
PAST TOP PICK
September 14, 2017

(Top Pick Feb 22/17, Up 3%) It has traded in line with others. It is a wonderfully run company with a deep pipeline into diabetes and arthritis. They are in the forefront of immunotherapies for arthritis. They are the leaders. 15.5 times forward earnings. It should trade in a double digit PE. He likes it for leadership and diversification.

Show full opinionHide full opinion
Merck & Company (MRK-N)
September 14, 2017

(Top Pick Feb 22/17, Up 3%) It has traded in line with others. It is a wonderfully run company with a deep pipeline into diabetes and arthritis. They are in the forefront of immunotherapies for arthritis. They are the leaders. 15.5 times forward earnings. It should trade in a double digit PE. He likes it for leadership and diversification.

DON'T BUY
DON'T BUY
June 21, 2017

Pfizer (PFE-N) or Merck (MRK-N)? Neither. These companies did very, very well back in the last part of the last century. Patent protection laws really haven’t given them enough of a boost to be able to cover the enormous costs of developing and testing the drugs, and there is a high failure rate. The companies have made massive consolidations. They’ve tried to grow by spending less. He would look at the Bio-Pharma area instead, such as Biogen (BIIB-Q) or Celgene (CELG-Q). Financially, these companies are in good shape and are growing.

Show full opinionHide full opinion

Pfizer (PFE-N) or Merck (MRK-N)? Neither. These companies did very, very well back in the last part of the last century. Patent protection laws really haven’t given them enough of a boost to be able to cover the enormous costs of developing and testing the drugs, and there is a high failure rate. The companies have made massive consolidations. They’ve tried to grow by spending less. He would look at the Bio-Pharma area instead, such as Biogen (BIIB-Q) or Celgene (CELG-Q). Financially, these companies are in good shape and are growing.

Showing 16 to 30 of 188 entries